Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 715 results

Media Release / Oct 18, 2017

Novartis drug Promacta® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
Media Release / Sep 25, 2017

Alcon DAILIES® teams up with US Olympians - world-class gymnast Laurie Hernandez and soccer star Tobin Heath - to launch the Invisible Edge campaign

Consumer education campaign highlights the important role of vision in giving "everyday" athletes an invisible edge on and off the fieldNew survey uncovers that clear eyesight is more important than…
Media Release / Sep 25, 2017

Alcon DAILIES® teams up with US Olympians - world-class gymnast Laurie Hernandez and soccer star Tobin Heath - to launch the Invisible Edge campaign
Media Release / Sep 14, 2017

Novartis teams up with actress, producer and activist Eva Longoria to launch Kiss This 4 MBC™ to generate research funding and support for the metastatic breast cancer community

- Kiss This 4 MBC goes beyond raising awareness of metastatic breast cancer to generate an increase in public support and research funds for the estimated 155,000 people living with this disease in…
Media Release / Sep 14, 2017

Novartis teams up with actress, producer and activist Eva Longoria to launch Kiss This 4 MBC™ to generate research funding and support for the metastatic breast cancer community
Media Release / Sep 13, 2017

Novartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data

- Cosentyx® (secukinumab) is the first and only fully human IL-17A antagonist to show sustained skin clearance rates at 5 years in Phase III in psoriasis(1)- Landmark data show that PASI 90 and PASI…
Media Release / Sep 13, 2017

Novartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data
Media Release / Aug 30, 2017

Multimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

- First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes1,2- Novel approach to cancer treatment…
Media Release / Aug 30, 2017

Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

- First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes1,2- Novel approach to cancer treatment…
Media Release / Aug 30, 2017

Multimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

‹ Previous page
1
…
38
39
40
41
42
43
44
…
72
› Next page